ArticleInvestigational new drugs2025

A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors.

Dan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.